scholarly journals Contribution of intestinal transporters to drug absorption and the implications for drug discovery and development (2) : efflux transporters

2006 ◽  
Vol 21 (2) ◽  
pp. 142-152 ◽  
Author(s):  
Takuo Ogihara ◽  
Noriko Okudaira
Keyword(s):  
Drug Discovery ◽  
Drug Absorption ◽  
Efflux Transporters ◽  
Drug Discovery And Development ◽  
Intestinal Transporters

Theoretical Predictions of Drug Absorption in Drug Discovery and Development

2002 ◽  
Vol 41 (11) ◽  
pp. 877-899 ◽  
Author(s):  
Patric Stenberg ◽  
Christel A.S. Bergstr??m ◽  
Kristina Luthman ◽  
Per Artursson
Keyword(s):  
Drug Discovery ◽  
Drug Absorption ◽  
Drug Discovery And Development ◽  
Theoretical Predictions

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

The State of the Art in Anti-Malarial Drug Discovery and Development

2011 ◽  
Vol 999 (999) ◽  
pp. 1-29
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
The State ◽  
Drug Discovery And Development
Sign in / Sign up

Export Citation Format

Share Document